Neurodegenerative diseases, in which neuronal cells disintegrate, bring about deteriorations in cognitive functions as is evidenced in millions of Alzheimer patients. A major neuropeptide, vasoactive intestinal peptide (VIP), has been shown to be neuroprotective and to play an important role in the acquisition of learning and memory. A potent lipophilic analogue to VIP now has been synthesized, [stearyl- (6) (7) (8) . Cholinergic blockade, resulting in impairment of learning and memory, has been used as a model of this disease (9). Ethylcholine aziridium (AF64A) is a blocker of choline uptake and it is well established that intracerebroventricular (i.c.v.) administration of this drug can induce loss in cholinergic neurons at the basal forebrain (9-11). Despite this apparent progress, successful treatment of neurodegeneration associated with Alzheimer dementia remains elusive (1, 2, 12, 13) .
f3-amyloid peptide is a major component of the cerebral amyloid plaque in Alzheimer disease and has been shown to be neurotoxic. We have found a 70% loss in the number of neurons in rat cerebral cortical cultures treated with the f3-amyloid peptide (amino acids [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] in comparison to controls. This cell death was completely prevented by cotreatment with 0.1 pM [St-Nle '7] VIP. Furthermore, characteristic deficiencies in Alzheimer disease result from death of cholinergic neurons. Rats treated with a cholinergic blocker (ethylcholine aziridium) have been used as a model for cholinergic deficits. St-Nle-VIP injected intracerebroventricularly or delivered intranasally prevented impairments in spatial learning and memory associated with cholinergic blockade. These studies suggest both an unusual therapeutic strategy for treatment of Alzheimer deficiencies and a means for noninvasive peptide administration to the brain.
Senile dementia of the Alzheimer type afflicts 3-5 million people in the United States (1, 2) . Although the etiology of this disease remains unclear, recent studies have indicated that the /-amyloid peptide is excessively deposited in the brains of the patients, contributing to the neurodegenerative process, which leads to senility (3) (4) (5) . A major class of neurons that are known to be lost in Alzheimer disease are cholinergic neurons (6) (7) (8) . Cholinergic blockade, resulting in impairment of learning and memory, has been used as a model of this disease (9) . Ethylcholine aziridium (AF64A) is a blocker of choline uptake and it is well established that intracerebroventricular (i.c.v.) administration of this drug can induce loss in cholinergic neurons at the basal forebrain (9) (10) (11) . Despite this apparent progress, successful treatment of neurodegeneration associated with Alzheimer dementia remains elusive (1, 2, 12, 13) .
In the present study, we have explored the possibility that a neurotrophic peptide, vasoactive intestinal peptide (VIP) (14) (15) (16) , might provide neuroprotection in models of degeneration/cognitive impairment related to Alzheimer disease. This strategy is based on the demonstrated ability of VIP to protect neurons in the central nervous system from a variety of neurotoxic substances including tetrodotoxin (17) and the human immunodeficiency virus (HIV) envelope protein (18) , suggesting that this peptide can provide general neuroprotec-
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tion. Numerous anatomical studies combining immunohistochemistry, radioimmunoassays, receptor distribution (as reviewed in refs. 14 and 15), and gene expression studies (19) (20) (21) attest to the availability of VIP in brain areas important for cognitive functions, such as the cerebral cortex and the hippocampus. However, VIP expression is significantly decreased in the cerebral cortex of aged animals (22) . Blockade of VIP actions by a specific antagonist (23) or experimentally reduced VIP expression in transgenic animals (24) both resulted in behavioral deficits associated with impairment of learning and memory. Furthermore, VIP may modulate brain activity through its ability to enhance cholinergic function (25) (26) (27) (28) . Although there is conflicting evidence concerning the role of VIP in dementia in general and in Alzheimer disease in particular, a study of immunoreactivity of VIP in Alzheimer and control brains showed a significant reduction of VIP immunoreactivity in the cerebral cortex, especially in the insular and angulate cortex of Alzheimer patients (29) . However, it has never been determined whether this reduction was the cause or the result of deterioration of the cortex. The present work clearly indicated that a new lipophilic VIP analogue (30) (31) (32) provided potent and effective protection from neuronal cell death produced by /3-amyloid peptide in vitro and from impairment of spatial learning produced by cholinergic blockade in vivo.
MATERIALS AND METHODS
Peptide Syntheses. Peptide syntheses were carried out manually according to the solid-phase strategy employing optimum side chain protection as before (30) (31) (32) . Products were purified by gel chromatography on a Sephadex G-25 column, followed by reversed-phase HPLC on a semipreparative C8 column (Lichrosorb RP-8) ( (10 -3 M) was dissolved in absolute ethanol and serially diluted in distilled sterile phosphate-buffered saline. Fifteen microliters of the test peptide was then added to 1.5 ml of tissue culture medium to yield the final desired concentration. Under these conditions, the highest percentage of ethanol used was 0.001%. At this concentration and even at 0.01% ethanol, there was no effect on neuronal survival. In the case of VIP 0.01 M acetic acid was used instead of ethanol (17, 18) . The astrocyte feeder layer contained confluent, dividing cells at days 9 and 14. Cell division was determined by thymidine incorporation performed as described (36) and astroglial cell content was evaluated by specific immunostaining with glial fibrillar acidic protein antibodies and iodinated secondary antibodies. Results have indicated no apparent change between ,B-amyloidtreated and untreated cultures. After 14 days in culture, cells were fixed for immunocytochemistry and stained with antibodies against neuron-specific enolase (a neuronal marker). Neuronal cell counts were executed on 40 fields, with a total area of 26 mm2. Neurons were counted without knowledge of type of treatment as described (e.g., see refs. 17 and 18). Experiments were performed at least four times, each in triplicate. There was no effect of vehicle treatment on the cell counts in all experimental paradigms.
In [9] [10] [11] . In one set of experiments, animals were stereotaxically implanted during injection to allow drug application under 10% chloral hydrate anesthesia. The cannula was a stainless steel needle (21 gauge; Becton Dickinson-i.e., a cannula of a 21G needle was attached to the 25G needle used for the AF64A injection). The cannula was placed 1 mm posterior and 1-1.5 mm lateral to bregma, 3.5 mm below the surface of the cranium. Only one brain side was cannulated (the left side). Four stainless steel screws were placed around the cannula and acrylic dental cement was used to anchor the cannula. Placement in the lateral ventricle was subsequently confirmed by injection of dye.
Drug Administration and Behavioral Testing. Drug treatment was initiated 7-10 days after cannulation in animals that were injected with AF64A and cannulated. These animals were divided into two equal groups and were thereafter injected daily (i.c.v.), one group with saline (4 ,ul per animal; control rats) and the other with 100 ng per 4 ,ul of [St-Nlel7]VIP for each animal. The control rats were chronically injected with saline through the cannula.
In a second set of experiments, animals treated with AF64A but not cannulated received daily nasal administration of [St-Nle17]VIP dissolved in 10% sefsol and 40% isopropanol (32) at a concentration of either 10 anesthetized by diethyl ether prior to nasal administration. After 7 days of drug administration, behavioral assays were conducted for an additional 11 days. Drugs were injected i.c.v. 4 hr prior to behavioral testing or applied by nasal administration 1 hr prior to testing. All animals were daily treated with 50,000 units of durabiotic antibiotics to avoid infection.
For behavioral test procedures, rats were placed in a circular pool, 1.26 m in diameter, 0.2 m deep, equipped with a clear Plexiglas column, with a 13.3-cm platform reaching just below the surface of the water (22-24°C). The latency of reaching the platform was recorded for each rat (in seconds) and the decreases over days of training reflected learning and memory (23, 24, (37) (38) (39) . Rats were tested once daily. The cutoff time for the latency to reach the platform was 300 sec. If the animal did not find the platform after 300 sec, it was then placed on the platform for 20 sec. Two types of experiments were performed. In one type of experiment, the platform was set in the middle of the pool. In another type of experiment, the platform was set in the middle of one quadrant of the pool. Each day (each trial) the animals were started from a different start point. If we consider the pool as a clock, then the animals were placed at hour positions 6:00, 9:00, 12:00, and 3:00 repeatedly, in the same order. In some experiments, to avoid bias related to possible changes in motor activity in the various treatment groups, a probe trial that assessed spatial memory was also utilized as follows. After 9 days of training and testing, the platform was removed and on day 10 the animals were subjected to swimming in the pool (for 300 sec) without the platform; in these experiments, the time spent by the rats in the quadrant of the pool where the platform used to be was recorded (39) . To evaluate for possible motor deficits that could impair performance, unrelated to memory, in some experiments, on day 11 of testing the animals were allowed to swim to an exposed platform.
Biodistribution Following Intranasal Administration. [StNle'7]VIP was radioiodinated as described (30, 32) (40, 41 (42) .
[St-Nle17]VIP protected cortical neurons from the toxic effect of the ,B-amyloid peptide fragment with severalfold greater potency than that observed for VIP (Fig. 1B) exhibiting maximal potency at 10-14 M (P < 0.001, one-way analysis of variance, Student-Newman-Keuls method). Importantly, the neuroprotective action of [St-Me17]VIP was efficacious over a range of concentrations broader than that of VIP. In cultures not treated with the ,3-amyloid peptide (Fig. 1C) (Fig. 4) (Fig. 4B) . Fig. 4C depicts the results of a probe trial that assessed spatial memory. After 9 days of training and testing, the platform was removed and on day 10 the animals were subjected to swimming in a pool without the platform. It was apparent from the probe trial that there was memory was apparent both in control rats (P < 0.05) and in AF64A-treated animals (P < 0.007). To evaluate for possible motor deficits that could impair performance unrelated to memory, on day 11 of testing the animals were allowed to swim to an exposed platform and, as evidenced in Fig. 4A With normal aging, there is a dramatic reduction in VIP mRNA in the cerebral cortex (22 (34) , preferring the high-affinity site and not recognizing the receptor associated with adenylate cyclase activation (42) . The neurotrophic activity associated with VIP is apparently mediated through high-affinity receptors on glial cells (34, 46, 47) that are linked to mobilization of calcium (48) and the release of survival-promoting substances (46, 47) . Our working hypothesis is that the neuroprotective action of VIP apparent in the Alzheimer models presented here is mediated through these glia-derived molecules. We further speculate that interference with the action of these endogenous molecules is a part of the etiology of Alzheimer disease. The behavioral model that included the cholinotoxin AF64A is known to induce neuronal cell loss (9) (10) (11) , and specific neuronal cell loss has been associated with learning impairments (e.g., see ref. 39 AF64A-treated animals. In addition, when the animals of the various experimental groups were allowed to swim to an exposed platform, no differences were observed, indicating no motor deficits. In all tests performed, the effect of the AF64A was not apparent after 10 days of training compared to vehicle-treated control animals, suggesting recovery. In the probe trial, an influence of [St-Nle17]VIP on the control animals was apparent. In contrast, an influence of [StNle17]VIP on the latency of reaching the platform in control animals was not seen (Fig. 4B) , emphasizing the significance of the additional probe trial, which picked up subtle differences (Fig. 4C) . The effect of [St-Nle'7]VIP on control animals may be mediated by maintenance of neuronal survival and activity.
Regardless of the molecular mechanism by which VIP analogues ameliorate Alzheimer-related dysfunctions, the emerging possibilities of genetic counseling (49) and early detection with the advent of positron emission tomography (12, 13) 
